Vyome Holdings (H1O) Risk Analysis

If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our shares of common stock after the closing of the Merger, the trading price of our shares of common stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Certain of our shareholders are subject to lock-up provisions that restrict their ability to transfer shares of our common stock or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security convertible into or exercisable or exchanged for the Company until 360 days from the date of Closing of the Merger, provided that 20% of the shares subject to the lock-up will be released from the restrictions in the lock-up agreement on the 91st day after the closing and the remainder will be released from the restrictions in equal increments every 30 days thereafter.

The trading market for shares of our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts commence coverage of the Company, the trading price for its shares would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issues an adverse opinion regarding us, our business model, our intellectual property or our share performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our share price would likely decline. If one or more of these analysts cease coverage or fail to publish reports regularly, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.

We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as shares of our common stock or, alternatively, may have dividend, liquidation or other preferences to shares of our common stock. The issuance of additional equity securities will dilute the holdings of existing shareholders and may reduce the share price of shares of our common stock. In addition, if our board of directors elects to institute new equity incentive plans or increase the number of shares available for future grant under its existing equity incentive plan, stockholders may experience additional dilution, which could cause our stock price to fall. Pursuant to certain Registration Rights Agreements entered into in connection with the Merger, certain shareholders of Vyome can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of its other securities. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Lock-Up Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of the our securities. If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to the Vyome Assets or any product candidates, or grant licenses on terms unfavorable to us. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of the Vyome Assets.